allergies

News

DBV gets peanut allergy therapy programme back on track

Shares in DBV have shot up on phase 3 results that set up a US filing for its peanut allergy therapy. which could plug a looming hole in the market.

News

Man sneezes and puts hand out to viewer to keep distance

Allergy Tx plots grass pollen jab launch after German okay

Allergy Therapeutics has had its grass pollen allergy treatment Grassmuno approved in Germany, its first market, setting up a launch early next year.

News

Remedy Meds buys telehealth rival in $500m marriage

Telehealth startup Remedy Meds has expanded its position in the US market at a stroke with a $500m-plus deal to buy Thirty Madison.

News

First-in-class hay fever immunotherapy backed for NHS use

A once-daily tablet that can help people suffering from hay fever caused by tree pollen, Alk-Abelló's Itulazax, has been recommended for NHS use.

News

A nasal spray in the palm of a person's hand

First intranasal anaphylaxis drug launches in Germany

An alternative to epinephrine autoinjectors that can be delivered by a nasal spray has been launched in Germany, its first market, by ALK-Abello.

News

FDA clears first anaphylaxis nasal spray at second attempt

ARS Pharma has claimed FDA approval for its epinephrine nasal spray neffy, becoming the first needle-free alternative to EpiPen-style autoinjectors for serious allergic reactions.

DBV gets peanut allergy therapy programme back on track

Allergy Tx plots grass pollen jab launch after German okay

Remedy Meds buys telehealth rival in $500m marriage

First-in-class hay fever immunotherapy backed for NHS use

First intranasal anaphylaxis drug launches in Germany

FDA clears first anaphylaxis nasal spray at second attempt

CEPI steps in to fund Moderna's pandemic flu jab

How to meet your physicians where they are online

allergies

Editor's Picks